Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
KemPharm to Present at The MoneyShow Orlando Investor Conference | ||||||
By: Nasdaq / GlobeNewswire - 31 Jan 2018 | Back to overview list |
|||||
CORALVILLE, Iowa, Jan. 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at “The MoneyShow Orlando,” one of the largest annual retail investor conferences held in the U.S. The conference will take place at the Omni Orlando Resort ChampionsGate, February 8-11, 2018. Dr. Mickle will deliver a strategic presentation on the opportunities and outlook for KemPharm’s prodrug development platform, utilizing the company’s proprietary LAT™ (Ligand Activated Therapy) platform. KemPharm at The MoneyShow Orlando, February 8-11, 2018: A copy of the presentation will be made available within the Investor Relations section of KemPharm’s website at: www.KemPharm.com About MoneyShow: About KemPharm: Caution Concerning Forward Looking Statements: This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2016, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
|
||||||
|
||||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |